EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer

Chuan-Teng Liu, Chun-Chieh Yeh, Tsai-Chen Wu, Chia-Hsin Lin, Yi-Ting Kuo, Yoichiro Iwakura, Yuan-Ji Day, Charles Drake, Vedran Radojcic, Ying-Chyi Song iD, Heng-Hsiung Wu iD, Hung-Rong Yen iD

Advanced Science · 2026-03 · 13 (16)

DOI: 10.1002/advs.202513020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.01.2026. Verfasst von Chuan-Teng Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Traditional Chinese Medicine, Department of Medical Research, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Uncoupling Protein 2, Pancreatic Neoplasms, Interleukin-17, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University, Taiwan, Ministry of Science and Technology, Taiwan, China Medical University Hospital Cancer Research Center of Excellence, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains resistant to immunotherapy due to its immunosuppressive tumor microenvironment (TME) and impaired metabolic fitness of effector T cells. Here, we show that targeting UCP2 reprograms T‐cell metabolism, and that dual blockade with IL‐17 further enhance antitumor responses in PDAC. Pharmacologic UCP2 inhibition with genipin increases IFN‐γ production by CD8⁺ T cells through IL‐12R/STAT4/mTOR signaling and enhanced mitochondrial oxidative phosphorylation, promoting a T‐bet‐driven cytotoxic program. However, UCP2 inhibition alone does not suppress tumor growth. Accordingly, combination with IL‐17 depletion synergistically augments Tc1/Th1 responses, reduces myeloid‐derived suppressor cells (MDSCs), and improves survival across multiple PDAC models, including genetically engineered and orthotopic systems. CD8⁺ T‐cell depletion abrogates these effects. Moreover, UCP2 inhibition enhances IFN‐γ production in patient‐derived PBMCs and tumor‐infiltrating lymphocytes. These findings identify UCP2 as a metabolic checkpoint in cytotoxic T cells and support dual UCP2/IL‐17 blockade as a promising immunotherapeutic strategy for PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uncoupling Protein 2Pancreatic NeoplasmsInterleukin-17Carcinoma, Pancreatic DuctalT-LymphocytesAnimalsMiceHumansTumor MicroenvironmentCell Line, TumorCD8-Positive T-LymphocytesImmunotherapyMetabolic Reprogramming

Stichwörter der Autor:innen

cytotoxic T cellimmunotherapyinterleukin‐17pancreatic canceruncoupling protein 2

Substanzen

Uncoupling Protein 2Interleukin-17UCP2 protein, humanUcp2 protein, mouse

Autor:innen und Institutionen

  • Research Center for Traditional Chinese Medicine, Department of Medical Research, China Medical University, Taichung, Taiwan.
  • Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
  • Department of Surgery, Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
  • Graduate Institute of Chinese Medicine, School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
  • Department of Chinese Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.

ORCID-Profile: Ying-Chyi Song, Heng-Hsiung Wu, Hung-Rong Yen

Förderung

  • China Medical University, Taiwan
  • Ministry of Science and Technology, Taiwan
  • China Medical University Hospital Cancer Research Center of Excellence, Ministry of Health and Welfare
  • China Medical University Hospital
  • Chinese Medicine Research Center, China Medical University" from the Featured Areas Research Center Program within the framework of the Higher Education Sprout…

Zitieren

APA

Liu, C. T., Yeh, C. C., Wu, T. C., Lin, C. H., Kuo, Y. T., Iwakura, Y., Day, Y. J., Drake, C., Radojcic, V., Song, Y. C., Wu, H. H., & Yen, H. R. (2026). Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer. Advanced Science, 13(16). https://doi.org/10.1002/advs.202513020

Vancouver

Liu CT, Yeh CC, Wu TC, Lin CH, Kuo YT, Iwakura Y, et al. Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer. Advanced Science. 2026;13(16). doi:10.1002/advs.202513020

BibTeX
@article{Liu2026,
  author = {Liu, Chuan-Teng and Yeh, Chun-Chieh and Wu, Tsai-Chen and Lin, Chia-Hsin and Kuo, Yi-Ting and Iwakura, Yoichiro and Day, Yuan-Ji and Drake, Charles and Radojcic, Vedran and Song, Ying-Chyi and Wu, Heng-Hsiung and Yen, Hung-Rong},
  title = {Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {16},
  doi = {10.1002/advs.202513020}
}
Kostenlos starten →